

SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



Orbifloxacin Liquid Formulation

| | | | |
|---------|----------------|--------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 09/30/2023 |
| 5.0 | 04/14/2025 | 785439-00019 | Date of first issue: 06/28/2016 |

SECTION 1. IDENTIFICATION

Product name : Orbifloxacin Liquid Formulation

Manufacturer or supplier's details

Company name of supplier : Merck & Co., Inc
Address : 126 E. Lincoln Avenue
Rahway, New Jersey U.S.A. 07065
Telephone : 908-740-4000
Emergency telephone : 1-908-423-6000
E-mail address : EHSDATASTEWARD@merck.com

Recommended use of the chemical and restrictions on use

Recommended use : Veterinary product
Restrictions on use : Not applicable

SECTION 2. HAZARDS IDENTIFICATION


GHS classification in accordance with the OSHA Hazard Communication Standard (29 CFR 1910.1200)

Reproductive toxicity : Category 2
Specific target organ toxicity : Category 2 (Eye)
- repeated exposure (Oral)

Other hazards

None known.

GHS label elements

Hazard pictograms : 

Signal Word : Warning

Hazard Statements : H361d Suspected of damaging the unborn child.
H373 May cause damage to organs (Eye) through prolonged or repeated exposure if swallowed.

Precautionary Statements : **Prevention:**
P201 Obtain special instructions before use.
P202 Do not handle until all safety precautions have been read and understood.
P260 Do not breathe mist or vapors.
P280 Wear protective gloves, protective clothing, eye protection and face protection.
Response:
P308 + P313 IF exposed or concerned: Get medical attention.

SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



Orbifloxacin Liquid Formulation

Version 5.0 Revision Date: 04/14/2025 SDS Number: 785439-00019 Date of last issue: 09/30/2023
Date of first issue: 06/28/2016

Storage:

P405 Store locked up.

Disposal:

P501 Dispose of contents and container to an approved waste disposal plant.

SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

Components

| Chemical name | CAS No./Unique ID | Concentration (% w/w) | Trade secret |
|------------------|-------------------|-----------------------|--------------|
| Propylene glycol | 57-55-6* | $\geq 7 - \leq 13$ | TSC |
| Orbifloxacin | 113617-63-3* | $\geq 1 - \leq 5$ | TSC |
| Silicon dioxide | 7631-86-9* | $\geq 0.5 - \leq 1.5$ | TSC |
| Lactic acid | 50-21-5* | $\geq 0.5 - \leq 1.5$ | TSC |
| Sodium hydroxide | 1310-73-2* | $\geq 0.5 - \leq 1.5$ | TSC |

* Indicates that the identifier is a CAS No.

TSC- the actual concentration or concentration range is withheld as a trade secret

SECTION 4. FIRST AID MEASURES

- General advice : In the case of accident or if you feel unwell, seek medical advice immediately.
When symptoms persist or in all cases of doubt seek medical advice.
- If inhaled : If inhaled, remove to fresh air.
Get medical attention.
- In case of skin contact : In case of contact, immediately flush skin with soap and plenty of water.
Remove contaminated clothing and shoes.
Get medical attention.
Wash clothing before reuse.
Thoroughly clean shoes before reuse.
- In case of eye contact : Flush eyes with water as a precaution.
Get medical attention if irritation develops and persists.
- If swallowed : If swallowed, DO NOT induce vomiting.
Get medical attention.
Rinse mouth thoroughly with water.
- Most important symptoms and effects, both acute and delayed : Suspected of damaging the unborn child.
May cause damage to organs through prolonged or repeated exposure if swallowed.
- Protection of first-aiders : First Aid responders should pay attention to self-protection,

SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



Orbifloxacin Liquid Formulation

| | | | |
|---------|----------------|--------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 09/30/2023 |
| 5.0 | 04/14/2025 | 785439-00019 | Date of first issue: 06/28/2016 |

Notes to physician : and use the recommended personal protective equipment when the potential for exposure exists (see section 8).
: Treat symptomatically and supportively.

SECTION 5. FIRE-FIGHTING MEASURES

Suitable extinguishing media : Water spray
Alcohol-resistant foam
Carbon dioxide (CO₂)
Dry chemical

Unsuitable extinguishing media : None known.

Specific hazards during fire fighting : Exposure to combustion products may be a hazard to health.

Hazardous combustion products : Carbon oxides
Metal oxides

Specific extinguishing methods : Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.
Use water spray to cool unopened containers.
Remove undamaged containers from fire area if it is safe to do so.
Evacuate area.

Special protective equipment for fire-fighters : In the event of fire, wear self-contained breathing apparatus.
Use personal protective equipment.

SECTION 6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protective equipment and emergency procedures : Use personal protective equipment.
Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

Environmental precautions : Avoid release to the environment.
Prevent further leakage or spillage if safe to do so.
Prevent spreading over a wide area (e.g., by containment or oil barriers).
Retain and dispose of contaminated wash water.
Local authorities should be advised if significant spillages cannot be contained.

Methods and materials for containment and cleaning up : Soak up with inert absorbent material.
For large spills, provide diking or other appropriate containment to keep material from spreading. If diked material can be pumped, store recovered material in appropriate container.
Clean up remaining materials from spill with suitable absorbent.
Local or national regulations may apply to releases and

SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



Orbifloxacin Liquid Formulation

Version 5.0 Revision Date: 04/14/2025 SDS Number: 785439-00019 Date of last issue: 09/30/2023
Date of first issue: 06/28/2016

disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable. Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

SECTION 7. HANDLING AND STORAGE

- Technical measures : See Engineering measures under EXPOSURE CONTROLS/PERSONAL PROTECTION section.
- Local/Total ventilation : Use only with adequate ventilation.
- Advice on safe handling : Do not breathe mist or vapors.
Do not swallow.
Avoid contact with eyes.
Avoid prolonged or repeated contact with skin.
Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment
Take care to prevent spills, waste and minimize release to the environment.
- Conditions for safe storage : Keep in properly labeled containers.
Store locked up.
Store in accordance with the particular national regulations.
- Materials to avoid : Do not store with the following product types:
Strong oxidizing agents
Gases

SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Ingredients with workplace control parameters

| Components | CAS-No. | Value type (Form of exposure) | Control parameters / Permissible concentration | Basis |
|------------------|-------------|-------------------------------|---|-----------|
| Propylene glycol | 57-55-6 | TWA | 10 mg/m ³ | US WEEL |
| Orbifloxacin | 113617-63-3 | TWA | 0.2 mg/m ³ (OEB 2) | Internal |
| Silicon dioxide | 7631-86-9 | TWA (Dust) | 20 Million particles per cubic foot (Silica) | OSHA Z-3 |
| | | TWA (Dust) | 80 mg/m ³ / %SiO ₂ (Silica) | OSHA Z-3 |
| | | TWA | 6 mg/m ³ (Silica) | NIOSH REL |
| Sodium hydroxide | 1310-73-2 | C | 2 mg/m ³ | ACGIH |
| | | C | 2 mg/m ³ | NIOSH REL |
| | | TWA | 2 mg/m ³ | OSHA Z-1 |

- Engineering measures : Use appropriate engineering controls and manufacturing

SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



Orbifloxacin Liquid Formulation

| | | | |
|---------|----------------|--------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 09/30/2023 |
| 5.0 | 04/14/2025 | 785439-00019 | Date of first issue: 06/28/2016 |

technologies to control airborne concentrations (e.g., drip-less quick connections).

All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.

Laboratory operations do not require special containment.

Personal protective equipment

- | | | |
|--------------------------|---|---|
| Respiratory protection | : | General and local exhaust ventilation is recommended to maintain vapor exposures below recommended limits. Where concentrations are above recommended limits or are unknown, appropriate respiratory protection should be worn. Follow OSHA respirator regulations (29 CFR 1910.134) and use NIOSH/MSHA approved respirators. Protection provided by air purifying respirators against exposure to any hazardous chemical is limited. Use a positive pressure air supplied respirator if there is any potential for uncontrolled release, exposure levels are unknown, or any other circumstance where air purifying respirators may not provide adequate protection. |
| Hand protection | : | |
| Material | : | Chemical-resistant gloves |
| Eye protection | : | Wear safety glasses with side shields or goggles. If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles. Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols. |
| Skin and body protection | : | Work uniform or laboratory coat. |
| Hygiene measures | : | If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contaminated clothing before re-use. The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls. |

SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES

- | | | |
|------------------------------|---|-------------------|
| Appearance | : | suspension |
| Color | : | light brown |
| Odor | : | odorless |
| Odor Threshold | : | No data available |
| pH | : | No data available |
| Melting point/freezing point | : | No data available |

SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



Orbifloxacin Liquid Formulation

| | | | |
|---------|----------------|--------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 09/30/2023 |
| 5.0 | 04/14/2025 | 785439-00019 | Date of first issue: 06/28/2016 |

| | | |
|--|---|--|
| Initial boiling point and boiling range | : | No data available |
| Flash point | : | No data available |
| Evaporation rate | : | No data available |
| Flammability (solid, gas) | : | Not applicable |
| Flammability (liquids) | : | No data available |
| Upper explosion limit / Upper flammability limit | : | No data available |
| Lower explosion limit / Lower flammability limit | : | No data available |
| Vapor pressure | : | No data available |
| Relative vapor density | : | No data available |
| Relative density | : | No data available |
| Density | : | No data available |
| Solubility(ies) | : | |
| Water solubility | : | No data available |
| Partition coefficient: n-octanol/water | : | No data available |
| Autoignition temperature | : | No data available |
| Decomposition temperature | : | No data available |
| Viscosity | : | |
| Viscosity, kinematic | : | No data available |
| Explosive properties | : | Not explosive |
| Oxidizing properties | : | The substance or mixture is not classified as oxidizing. |
| Molecular weight | : | No data available |
| Particle characteristics | : | |
| Particle size | : | No data available |

SECTION 10. STABILITY AND REACTIVITY

| | | |
|--------------------|---|--|
| Reactivity | : | Not classified as a reactivity hazard. |
| Chemical stability | : | Stable under normal conditions. |

SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



Orbifloxacin Liquid Formulation

| | | | |
|---------|----------------|--------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 09/30/2023 |
| 5.0 | 04/14/2025 | 785439-00019 | Date of first issue: 06/28/2016 |

Possibility of hazardous reactions : Can react with strong oxidizing agents.

Conditions to avoid : None known.

Incompatible materials : Oxidizing agents

Hazardous decomposition products : No hazardous decomposition products are known.

SECTION 11. TOXICOLOGICAL INFORMATION

Information on likely routes of exposure

Inhalation
Skin contact
Ingestion
Eye contact

Acute toxicity

Not classified based on available information.

Product:

Acute oral toxicity : Acute toxicity estimate: > 5,000 mg/kg
Method: Calculation method

Acute inhalation toxicity : Acute toxicity estimate: > 200 mg/l
Exposure time: 4 h
Test atmosphere: dust/mist
Method: Calculation method

Components:

Propylene glycol:

Acute oral toxicity : LD50 (Rat): 22,000 mg/kg

Acute inhalation toxicity : LC50 (Rat): > 44.9 mg/l
Exposure time: 4 h
Test atmosphere: dust/mist

Acute dermal toxicity : LD50 (Rabbit): > 2,000 mg/kg
Assessment: The substance or mixture has no acute dermal toxicity

Orbifloxacin:

Acute oral toxicity : LD50 (Rat): > 3,000 mg/kg
Remarks: No mortality observed at this dose.

LD50 (Mouse): > 2,000 mg/kg
Remarks: No mortality observed at this dose.

LD50 (Dog): > 600 mg/kg
Symptoms: Vomiting
Remarks: No mortality observed at this dose.

Acute inhalation toxicity : Remarks: No data available

SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



Orbifloxacin Liquid Formulation

| | | | |
|---------|----------------|--------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 09/30/2023 |
| 5.0 | 04/14/2025 | 785439-00019 | Date of first issue: 06/28/2016 |

Acute dermal toxicity : Remarks: No data available

Acute toxicity (other routes of administration) : LD50 (Rat): > 200 mg/kg
Application Route: Intramuscular

LD50 (Mouse): 500 mg/kg
Application Route: Intramuscular

LD50 (Rat): 233 mg/kg
Application Route: Intravenous

LD50 (Mouse): 250 mg/kg
Application Route: Intravenous

Silicon dioxide:

Acute oral toxicity : LD50 (Rat): > 5,000 mg/kg
Method: OECD Test Guideline 401

Acute inhalation toxicity : LC50 (Rat): > 2.08 mg/l
Exposure time: 4 h
Test atmosphere: dust/mist
Assessment: The substance or mixture has no acute inhalation toxicity

Acute dermal toxicity : LD50 (Rabbit): > 5,000 mg/kg

Lactic acid:

Acute oral toxicity : LD50 (Rat): > 2,000 mg/kg
Remarks: Based on data from similar materials

Acute inhalation toxicity : LC50 (Rat): > 5 mg/l
Exposure time: 4 h
Test atmosphere: dust/mist
Method: OECD Test Guideline 403
Assessment: Corrosive to the respiratory tract.
Remarks: Based on data from similar materials

Acute dermal toxicity : LD50 (Rabbit): > 2,000 mg/kg
Assessment: The substance or mixture has no acute dermal toxicity
Remarks: Based on data from similar materials

Sodium hydroxide:

Acute inhalation toxicity : Assessment: Corrosive to the respiratory tract.

Skin corrosion/irritation

Not classified based on available information.

Product:

Species : Rabbit

SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



Orbifloxacin Liquid Formulation

| | | | |
|---------|----------------|--------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 09/30/2023 |
| 5.0 | 04/14/2025 | 785439-00019 | Date of first issue: 06/28/2016 |

Result : No skin irritation

Components:

Propylene glycol:

| | |
|---------|---------------------------|
| Species | : Rabbit |
| Method | : OECD Test Guideline 404 |
| Result | : No skin irritation |

Orbifloxacin:

| | |
|---------|----------------------|
| Species | : Rabbit |
| Method | : Draize Test |
| Result | : No skin irritation |

Silicon dioxide:

| | |
|---------|---------------------------|
| Species | : Rabbit |
| Method | : OECD Test Guideline 404 |
| Result | : No skin irritation |

Lactic acid:

| | |
|---------|--|
| Species | : Rabbit |
| Method | : OECD Test Guideline 404 |
| Result | : Corrosive after 1 to 4 hours of exposure |
| Remarks | : Based on data from similar materials |

Sodium hydroxide:

| | |
|--------|---|
| Result | : Corrosive after 3 minutes or less of exposure |
|--------|---|

Serious eye damage/eye irritation

Not classified based on available information.

Product:

| | |
|---------|-----------------------|
| Species | : Rabbit |
| Result | : Mild eye irritation |

Components:

Propylene glycol:

| | |
|---------|---------------------------|
| Species | : Rabbit |
| Result | : No eye irritation |
| Method | : OECD Test Guideline 405 |

Orbifloxacin:

| | |
|---------|-----------------------|
| Species | : Rabbit |
| Result | : Mild eye irritation |
| Method | : Draize Test |

SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



Orbifloxacin Liquid Formulation

| | | | |
|---------|----------------|--------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 09/30/2023 |
| 5.0 | 04/14/2025 | 785439-00019 | Date of first issue: 06/28/2016 |

Silicon dioxide:

| | |
|---------|---------------------------|
| Species | : Rabbit |
| Result | : No eye irritation |
| Method | : OECD Test Guideline 405 |

Lactic acid:

| | |
|---------|--|
| Species | : Chicken eye |
| Remarks | : Based on data from similar materials |

| | |
|--------|-----------------------------------|
| Result | : Irreversible effects on the eye |
|--------|-----------------------------------|

Sodium hydroxide:

| | |
|---------|-----------------------------------|
| Result | : Irreversible effects on the eye |
| Remarks | : Based on skin corrosivity. |

Respiratory or skin sensitization

Skin sensitization

Not classified based on available information.

Respiratory sensitization

Not classified based on available information.

Product:

| | |
|--------------------|--------------------------|
| Test Type | : Magnusson-Kligman-Test |
| Routes of exposure | : Dermal |
| Species | : Guinea pig |
| Result | : Not a skin sensitizer. |

Components:

Propylene glycol:

| | |
|--------------------|---------------------|
| Test Type | : Maximization Test |
| Routes of exposure | : Skin contact |
| Species | : Guinea pig |
| Result | : negative |

Orbifloxacin:

| | |
|--------------------|--------------------------|
| Test Type | : Maximization Test |
| Routes of exposure | : Dermal |
| Species | : Guinea pig |
| Result | : Not a skin sensitizer. |

Lactic acid:

| | |
|--------------------|--|
| Test Type | : Buehler Test |
| Routes of exposure | : Skin contact |
| Species | : Guinea pig |
| Result | : negative |
| Remarks | : Based on data from similar materials |

SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



Orbifloxacin Liquid Formulation

| | | | |
|---------|----------------|--------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 09/30/2023 |
| 5.0 | 04/14/2025 | 785439-00019 | Date of first issue: 06/28/2016 |

Sodium hydroxide:

| | |
|--------------------|--|
| Test Type | : Human repeat insult patch test (HRIPT) |
| Routes of exposure | : Skin contact |
| Result | : negative |

Germ cell mutagenicity

Not classified based on available information.

Components:

Propylene glycol:

| | |
|-----------------------|---|
| Genotoxicity in vitro | : Test Type: Bacterial reverse mutation assay (AMES) Result: negative Test Type: Chromosome aberration test in vitro Method: OECD Test Guideline 473 Result: negative |
| Genotoxicity in vivo | : Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay) Species: Mouse Application Route: Intraperitoneal injection Result: negative |

Orbifloxacin:

| | |
|-------------------------------------|---|
| Genotoxicity in vitro | : Test Type: Bacterial reverse mutation assay (AMES) Result: equivocal Test Type: Mouse Lymphoma Result: positive Test Type: Chromosomal aberration Test system: Human lymphocytes Result: positive |
| Genotoxicity in vivo | : Test Type: Micronucleus test Species: Mouse Cell type: Bone marrow Application Route: Intraperitoneal injection Result: negative Test Type: unscheduled DNA synthesis assay Species: Rat Cell type: Liver cells Application Route: Oral Result: negative |
| Germ cell mutagenicity - Assessment | : Weight of evidence does not support classification as a germ cell mutagen. |

Silicon dioxide:

| | |
|-----------------------|--|
| Genotoxicity in vitro | : Test Type: Bacterial reverse mutation assay (AMES) |
|-----------------------|--|

SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



Orbifloxacin Liquid Formulation

| | | | |
|---------|----------------|--------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 09/30/2023 |
| 5.0 | 04/14/2025 | 785439-00019 | Date of first issue: 06/28/2016 |

| | |
|----------------------|--|
| Genotoxicity in vivo | Method: OECD Test Guideline 471 |
| | Result: negative |
| Genotoxicity in vivo | : Test Type: Mutagenicity (in vivo mammalian bone-marrow cytogenetic test, chromosomal analysis) |
| | Species: Rat |
| | Application Route: Ingestion |
| | Result: negative |

Lactic acid:

| | |
|-----------------------|---|
| Genotoxicity in vitro | : Test Type: Bacterial reverse mutation assay (AMES) |
| | Method: OECD Test Guideline 471 |
| | Result: negative |
| | Remarks: Based on data from similar materials |
| | Test Type: In vitro mammalian cell gene mutation test |
| | Method: OECD Test Guideline 476 |
| | Result: negative |
| | Remarks: Based on data from similar materials |
| | Test Type: Chromosome aberration test in vitro |
| | Method: OECD Test Guideline 473 |
| | Result: negative |
| | Remarks: Based on data from similar materials |

Carcinogenicity

Not classified based on available information.

Components:

Propylene glycol:

| | |
|-------------------|-------------|
| Species | : Rat |
| Application Route | : Ingestion |
| Exposure time | : 2 Years |
| Result | : negative |

Orbifloxacin:

| | |
|-------------------|-------------------------|
| Species | : Rat |
| Application Route | : Oral |
| Exposure time | : 2 Years |
| NOAEL | : 200 mg/kg body weight |
| Result | : negative |

| | |
|-------------------|-------------------------|
| Species | : Mouse |
| Application Route | : Oral |
| Exposure time | : 2 Years |
| NOAEL | : 200 mg/kg body weight |
| Result | : negative |

Silicon dioxide:

| | |
|---------|-------|
| Species | : Rat |
|---------|-------|

SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



Orbifloxacin Liquid Formulation

| | | | |
|---------|----------------|--------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 09/30/2023 |
| 5.0 | 04/14/2025 | 785439-00019 | Date of first issue: 06/28/2016 |

| | |
|-------------------|-------------|
| Application Route | : Ingestion |
| Exposure time | : 103 weeks |
| Result | : negative |

Lactic acid:

| | |
|-------------------|--|
| Species | : Rat |
| Application Route | : Ingestion |
| Exposure time | : 2 Years |
| Result | : negative |
| Remarks | : Based on data from similar materials |

IARC No ingredient of this product present at levels greater than or equal to 0.1% is identified as probable, possible or confirmed human carcinogen by IARC.

OSHA No component of this product present at levels greater than or equal to 0.1% is on OSHA's list of regulated carcinogens.

NTP No ingredient of this product present at levels greater than or equal to 0.1% is identified as a known or anticipated carcinogen by NTP.

Reproductive toxicity

Suspected of damaging the unborn child.

Components:

Propylene glycol:

| | |
|------------------------------|---|
| Effects on fertility | : Test Type: Two-generation reproduction toxicity study Species: Mouse Application Route: Ingestion Result: negative |
| Effects on fetal development | : Test Type: Embryo-fetal development Species: Mouse Application Route: Ingestion Result: negative |

Orbifloxacin:

| | |
|------------------------------|---|
| Effects on fertility | : Test Type: Two-generation reproduction toxicity study Species: Rat Application Route: Oral General Toxicity Parent: NOAEL: 50 mg/kg body weight Early Embryonic Development: NOAEL: 50 mg/kg body weight Result: No adverse effects. |
| Effects on fetal development | : Test Type: Embryo-fetal development Species: Rat Application Route: Oral Embryo-fetal toxicity.: LOAEL: 333 mg/kg body weight Result: No teratogenic effects., Embryotoxic effects and adverse effects on the offspring were detected only at high maternally toxic doses |

SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



Orbifloxacin Liquid Formulation

| | | | |
|---------|----------------|--------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 09/30/2023 |
| 5.0 | 04/14/2025 | 785439-00019 | Date of first issue: 06/28/2016 |

Test Type: Embryo-fetal development
Species: Rabbit
Application Route: Oral
General Toxicity Maternal: NOAEL: 20 mg/kg body weight
Embryo-fetal toxicity.: NOAEL: 60 mg/kg body weight
Result: No effects on early embryonic development.,
Embryotoxic effects and adverse effects on the offspring were
detected only at high maternally toxic doses, Reduced
maternal body weight gain.

Test Type: Development
Species: Dog
Application Route: Oral
Developmental Toxicity: LOAEL: 2.5 mg/kg body weight
Result: Effects on postnatal development., Skeletal
malformations.

Reproductive toxicity - Assessment : Some evidence of adverse effects on development, based on
animal experiments.

Silicon dioxide:

Effects on fetal development : Test Type: Embryo-fetal development
Species: Rat
Application Route: Ingestion
Result: negative

Lactic acid:

Effects on fetal development : Test Type: Embryo-fetal development
Species: Mouse
Application Route: Ingestion
Result: negative

STOT-single exposure

Not classified based on available information.

STOT-repeated exposure

May cause damage to organs (Eye) through prolonged or repeated exposure if swallowed.

Product:

Target Organs : Eye
Assessment : May cause damage to organs through prolonged or repeated
exposure.

Repeated dose toxicity

Product:

Species : Dog
NOAEL : 22.5 mg/kg
LOAEL : 37.5 mg/kg
Application Route : Oral
Exposure time : 30 Days

SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



Orbifloxacin Liquid Formulation

| | | | |
|---------|----------------|--------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 09/30/2023 |
| 5.0 | 04/14/2025 | 785439-00019 | Date of first issue: 06/28/2016 |

| | | |
|-------------------|---|---|
| Symptoms | : | Gastrointestinal disturbance |
| Species | : | Dog |
| LOAEL | : | 75 mg/kg |
| Application Route | : | Oral |
| Exposure time | : | 10 Days |
| Symptoms | : | Salivation, Gastrointestinal disturbance, Vomiting |
| Species | : | Cat |
| LOAEL | : | 45 mg/kg |
| Application Route | : | Oral |
| Exposure time | : | 30 Days |
| Target Organs | : | Eye |
| Symptoms | : | Salivation, Lachrymation, Gastrointestinal disturbance, Liver disorders |

Components:

Propylene glycol:

| | | |
|-------------------|---|----------------|
| Species | : | Rat, male |
| NOAEL | : | >= 1,700 mg/kg |
| Application Route | : | Ingestion |
| Exposure time | : | 2 y |

Orbifloxacin:

| | | |
|-------------------|---|-------------------------------|
| Species | : | Rat |
| NOAEL | : | 20 mg/kg |
| LOAEL | : | 80 mg/kg |
| Application Route | : | Oral |
| Exposure time | : | 3 Months |
| Target Organs | : | Testis, Liver, Kidney, spleen |

| | | |
|-------------------|---|-----------|
| Species | : | Mouse |
| NOAEL | : | 80 mg/kg |
| LOAEL | : | 250 mg/kg |
| Application Route | : | Oral |
| Exposure time | : | 3 Months |

| | | |
|-------------------|---|------------------------------|
| Species | : | Juvenile dog |
| NOAEL | : | 50 mg/kg |
| LOAEL | : | 250 mg/kg |
| Application Route | : | Oral |
| Exposure time | : | 14 Days |
| Target Organs | : | Heart, Bone |
| Symptoms | : | Gastrointestinal disturbance |
| Remarks | : | mortality observed |

| | | |
|-------------------|---|--------------|
| Species | : | Juvenile dog |
| NOAEL | : | 2 mg/kg |
| LOAEL | : | 3 mg/kg |
| Application Route | : | Oral |
| Exposure time | : | 90 Days |
| Target Organs | : | Bone |

SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



Orbifloxacin Liquid Formulation

| | | | |
|---------|----------------|--------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 09/30/2023 |
| 5.0 | 04/14/2025 | 785439-00019 | Date of first issue: 06/28/2016 |

Remarks : No significant adverse effects were reported

Species : Dog
NOAEL : 37.5 mg/kg
Application Route : Oral
Exposure time : 30 Days

Species : Cat
NOAEL : 7.5 mg/kg
LOAEL : 22.5 mg/kg
Application Route : Oral
Exposure time : 1 Months
Symptoms : Gastrointestinal disturbance

Silicon dioxide:

Species : Rat
NOAEL : 1.3 mg/m³
Application Route : inhalation (dust/mist/fume)
Exposure time : 13 Weeks

Lactic acid:

Species : Rat
NOAEL : > 100 mg/kg
Application Route : Ingestion
Exposure time : 13 Weeks
Remarks : Based on data from similar materials

Species : Rat
LOAEL : 886 mg/kg
Application Route : Skin contact
Exposure time : 13 Weeks

Aspiration toxicity

Not classified based on available information.

Experience with human exposure

Components:

Orbifloxacin:

Ingestion : Symptoms: central nervous system effects, Gastrointestinal disturbance, liver function change, anaphylaxis, Rash
Remarks: May cause photosensitization.

SECTION 12. ECOLOGICAL INFORMATION

Ecotoxicity

Components:

Propylene glycol:

Toxicity to fish : LC50 (Oncorhynchus mykiss (rainbow trout)): 40,613 mg/l

SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



Orbifloxacin Liquid Formulation

| | | | |
|---------|----------------|--------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 09/30/2023 |
| 5.0 | 04/14/2025 | 785439-00019 | Date of first issue: 06/28/2016 |

| | |
|--|---|
| | Exposure time: 96 h |
| Toxicity to daphnia and other aquatic invertebrates | : EC50 (Ceriodaphnia dubia (water flea)): 18,340 mg/l Exposure time: 48 h |
| Toxicity to algae/aquatic plants | : ErC50 (Skeletonema costatum (marine diatom)): 19,300 mg/l Exposure time: 72 h Method: OECD Test Guideline 201 |
| Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity) | : NOEC (Ceriodaphnia dubia (water flea)): 13,020 mg/l Exposure time: 7 d |
| Toxicity to microorganisms | : NOEC (Pseudomonas putida): > 20,000 mg/l Exposure time: 18 h |

Silicon dioxide:

| | |
|---|--|
| Toxicity to fish | : LC50 (Danio rerio (zebra fish)): > 10,000 mg/l Exposure time: 96 h Method: OECD Test Guideline 203 |
| Toxicity to daphnia and other aquatic invertebrates | : EC50 (Daphnia magna (Water flea)): > 1,000 mg/l Exposure time: 24 h Method: OECD Test Guideline 202 |
| Toxicity to algae/aquatic plants | : EC50 (Desmodesmus subspicatus (green algae)): > 10,000 mg/l Exposure time: 72 h Method: OECD Test Guideline 201 Remarks: Based on data from similar materials NOEC (Desmodesmus subspicatus (green algae)): 10,000 mg/l Exposure time: 72 h Method: OECD Test Guideline 201 Remarks: Based on data from similar materials |

Lactic acid:

| | |
|---|--|
| Toxicity to fish | : LC50 (Danio rerio (zebra fish)): > 100 mg/l Exposure time: 96 h Method: OECD Test Guideline 203 Remarks: Based on data from similar materials |
| Toxicity to daphnia and other aquatic invertebrates | : EC50 (Daphnia magna (Water flea)): > 100 mg/l Exposure time: 48 h Method: OECD Test Guideline 202 Remarks: Based on data from similar materials |
| Toxicity to algae/aquatic plants | : ErC50 (Pseudokirchneriella subcapitata (green algae)): > 100 mg/l Exposure time: 72 h Method: OECD Test Guideline 201 Remarks: Based on data from similar materials |

SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



Orbifloxacin Liquid Formulation

| | | | |
|---------|----------------|--------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 09/30/2023 |
| 5.0 | 04/14/2025 | 785439-00019 | Date of first issue: 06/28/2016 |

| | |
|----------------------------|---|
| | NOEC (Pseudokirchneriella subcapitata (green algae)): > 100 mg/l Exposure time: 72 h Method: OECD Test Guideline 201 Remarks: Based on data from similar materials |
| Toxicity to microorganisms | : EC50: > 10 - 100 mg/l Exposure time: 3 h Method: OECD Test Guideline 209 Remarks: Based on data from similar materials |

Persistence and degradability

Components:

Propylene glycol:

| | |
|------------------|---|
| Biodegradability | : Result: Readily biodegradable. Biodegradation: 98.3 % Exposure time: 28 d Method: OECD Test Guideline 301F |
|------------------|---|

Lactic acid:

| | |
|------------------|---|
| Biodegradability | : Result: Not readily biodegradable. Remarks: Based on data from similar materials |
|------------------|---|

Bioaccumulative potential

Components:

Propylene glycol:

| | |
|--|--|
| Partition coefficient: n-octanol/water | : log Pow: -1.07 Method: Regulation (EC) No. 440/2008, Annex, A.8 |
|--|--|

Lactic acid:

| | |
|--|------------------|
| Partition coefficient: n-octanol/water | : log Pow: -0.62 |
|--|------------------|

Mobility in soil

No data available

Other adverse effects

No data available

SECTION 13. DISPOSAL CONSIDERATIONS

Disposal methods

| | |
|------------------------|---|
| Waste from residues | : Dispose of in accordance with local regulations. Do not dispose of waste into sewer. |
| Contaminated packaging | : Empty containers should be taken to an approved waste handling site for recycling or disposal. If not otherwise specified: Dispose of as unused product. |

SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



Orbifloxacin Liquid Formulation

| | | | |
|---------|----------------|--------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 09/30/2023 |
| 5.0 | 04/14/2025 | 785439-00019 | Date of first issue: 06/28/2016 |

SECTION 14. TRANSPORT INFORMATION

International Regulations

UNRTDG

Not regulated as a dangerous good

IATA-DGR

Not regulated as a dangerous good

IMDG-Code

Not regulated as a dangerous good

Transport in bulk according to IMO instruments

Not applicable for product as supplied.

Domestic regulation

49 CFR

Not regulated as a dangerous good

Special precautions for user

Not applicable

SECTION 15. REGULATORY INFORMATION

CERCLA Reportable Quantity

| Components | CAS-No. | Component RQ (lbs) | Calculated product RQ (lbs) |
|------------------|-----------|-----------------------|--------------------------------|
| Sodium hydroxide | 1310-73-2 | 1000 | 100000 |

SARA 304 Extremely Hazardous Substances Reportable Quantity

This material does not contain any components with a section 304 EHS RQ.

SARA 302 Extremely Hazardous Substances Threshold Planning Quantity

This material does not contain any components with a section 302 EHS TPQ.

SARA 311/312 Hazards : Reproductive toxicity
Specific target organ toxicity (single or repeated exposure)

SARA 313 : This material does not contain any chemical components with known CAS numbers that exceed the threshold (De Minimis) reporting levels established by SARA Title III, Section 313.

US State Regulations

Pennsylvania Right To Know

| | |
|--|-------------|
| Water | 7732-18-5 |
| Malt Extract | 8002-48-0 |
| 2-Propenoic acid, 2-methyl-, polymer with methyl 2-methyl-2-propenoate | 25086-15-1 |
| Propylene glycol | 57-55-6 |
| Orbifloxacin | 113617-63-3 |
| Silicon dioxide | 7631-86-9 |

SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



Orbifloxacin Liquid Formulation

| | | | |
|---------|----------------|--------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 09/30/2023 |
| 5.0 | 04/14/2025 | 785439-00019 | Date of first issue: 06/28/2016 |

Sodium hydroxide

1310-73-2

California List of Hazardous Substances

Silicon dioxide

7631-86-9

Sodium hydroxide

1310-73-2

California Permissible Exposure Limits for Chemical Contaminants

Silicon dioxide

7631-86-9

Sodium hydroxide

1310-73-2

The ingredients of this product are reported in the following inventories:

AICS : not determined


DSL : not determined

IECSC : not determined

SECTION 16. OTHER INFORMATION

Further information

NFPA 704:



HMIS® IV:

| | | |
|-----------------|---|---|
| HEALTH | * | 2 |
| FLAMMABILITY | | 1 |
| PHYSICAL HAZARD | | 0 |

HMIS® ratings are based on a 0-4 rating scale, with 0 representing minimal hazards or risks, and 4 representing significant hazards or risks. The "*" represents a chronic hazard, while the "/" represents the absence of a chronic hazard.

Full text of other abbreviations

| | |
|-----------------|---|
| ACGIH | : USA. ACGIH Threshold Limit Values (TLV) |
| NIOSH REL | : USA. NIOSH Recommended Exposure Limits |
| OSHA Z-1 | : USA. Occupational Exposure Limits (OSHA) - Table Z-1 Limits for Air Contaminants |
| OSHA Z-3 | : USA. Occupational Exposure Limits (OSHA) - Table Z-3 Mineral Dusts |
| US WEEL | : USA. Workplace Environmental Exposure Levels (WEEL) |
| ACGIH / C | : Ceiling limit |
| NIOSH REL / TWA | : Time-weighted average concentration for up to a 10-hour workday during a 40-hour workweek |

SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



Orbifloxacin Liquid Formulation

| | | | |
|---------|----------------|--------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 09/30/2023 |
| 5.0 | 04/14/2025 | 785439-00019 | Date of first issue: 06/28/2016 |

| | | |
|----------------|---|--|
| NIOSH REL / C | : | Ceiling value not be exceeded at any time. |
| OSHA Z-1 / TWA | : | 8-hour time weighted average |
| OSHA Z-3 / TWA | : | 8-hour time weighted average |
| US WEEL / TWA | : | 8-hr TWA |

AIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CERCLA - Comprehensive Environmental Response, Compensation, and Liability Act; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DOT - Department of Transportation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; EHS - Extremely Hazardous Substance; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; HMIS - Hazardous Materials Identification System; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; MSHA - Mine Safety and Health Administration; n.o.s. - Not Otherwise Specified; NFPA - National Fire Protection Association; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; RCRA - Resource Conservation and Recovery Act; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RQ - Reportable Quantity; SADT - Self-Accelerating Decomposition Temperature; SARA - Superfund Amendments and Reauthorization Act; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative

Sources of key data used to compile the Material Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

Revision Date : 04/14/2025

Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified

SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



Orbifloxacin Liquid Formulation

| | | | |
|---------|----------------|--------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 09/30/2023 |
| 5.0 | 04/14/2025 | 785439-00019 | Date of first issue: 06/28/2016 |

in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

US / Z8